Eisuke Fukuma, MD

Articles by Eisuke Fukuma, MD

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen

ByMamoru Fukuda, MD,Susumu Yamaguchi, MD,Tomohiko Ohta, MD,Yoshiaki Nakayama, MD,Haruki Ogata, MD,Kaname Shimizu, MD,Toru Nishikawa, MD,Yukihiro Adachi, MD,Eisuke Fukuma, MD

July 1st 1999

We evaluated combination therapy for advanced and recurrent breast cancer with cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), uracil and tegafur (UFT), and tamoxifen (Nolvadex) (CAUT), designed as

Latest Updated Articles

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen
Published: July 1st 1999 | Updated:

Eisuke Fukuma, MD

Articles by Eisuke Fukuma, MD

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen

Latest Updated Articles

Trending on CancerNetwork

KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma

ADCE-D01 Earns FDA Fast Track Designation in Soft Tissue Sarcoma

Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer

212Pb-Dotamtate Prolongs Responses in Advanced GEP-NETs

The Show and After Show Previews the 2025 ESMO Annual Congress